Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Jetstar to Charge for Overhead Cabin Bags From February 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
SAN DIEGO, March 08, 2018 -- Vical Incorporated (Nasdaq:VICL) today announced that the company will report financial results for the three months ended December 31, 2017, before the opening of trading on Thursday, March 15, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Thursday, March 15. The call will be open on a listen-only basis to any interested parties. The company will also provide a business update, including details on development programs in the conference call and webcast.
Conference Call
To listen to the conference call, dial in approximately ten minutes before the scheduled call to (323) 994-2083 (preferred), or (800) 562-8369 (toll-free), and reference confirmation code 2848082. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 2848082. The call also will be available live and archived through the events page at www.vical.com.
Invited participants may ask questions during the conference call. Others may submit questions before the call by e-mail addressed to [email protected] or by fax to (858) 646-1150. Submitted questions will be screened for appropriateness and general interest. Selected questions received with sufficient notice before the call will be answered as time permits at the end of the call. For further information, contact Vical’s Investor Relations department by phone at (858) 646-1127 or by email at [email protected].
About Vical
Vical develops biopharmaceutical products for the prevention and treatment of chronic or life-threatening infectious diseases, including antiviral and antifungal candidates in clinical development. Additional information on Vical is available at www.vical.com.
Contact:
Andrew Hopkins
(858) 646-1127
Website: www.vical.com
